Kahr Medical 
Welcome,         Profile    Billing    Logout  
 2 Products   1 Disease   2 Products   2 Trials   37 News 
  • ||||||||||  DSP-107 / Kahr Medical
    Trial completion date, Trial primary completion date, Monotherapy:  A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Oct 10, 2024   
    P1/2,  N=125, Recruiting, 
    Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Jun 2025 Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  DSP-FC 216 / Kahr Medical, Thomas Jefferson University
    DSP216  (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_784;    
    0155-17-HMO). Samples were received anonymously, and consent was not required.Download figure Open in new tab Download powerpoint Abstract 509 Figure 1
  • ||||||||||  DSP-FC 216 / Kahr Medical, Thomas Jefferson University
    DSP216 blocks HLA-G and CD47 signaling toward immune cells and restores anti-cancer activity () -  Feb 16, 2024 - Abstract #ITOC2024ITOC_19;    
    DSP216 prevents HLA-G mediated upregulation of the M2 marker CD163 on macrophages and eliminates HLA-G + CD47 + cancer cells by promoting macrophage-mediated phagocytosis and NK cell-mediated cytotoxicity. DSP216 is a novel bifunctional therapeutic that has the potential to reverse immunosuppressive signaling and unleash innate anti-cancer immune responses.
  • ||||||||||  DSP-107 / Kahr Medical
    Trial completion date, Trial primary completion date:  A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies (clinicaltrials.gov) -  Mar 13, 2023   
    P1,  N=36, Recruiting, 
    Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Sep 2024 Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Aug 2024
  • ||||||||||  DSP-107 / Kahr Medical
    Journal:  DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. (Pubmed Central) -  Mar 31, 2022   
    DSP107 is a novel, CD47 and 4-1BB targeting fusion protein with a differentiated safety, binding and pharmacodynamic profile compared to other CD47 and 4-1BB targeting agents. DSP107 effectively (re)activated innate and adaptive anticancer immune responses and may be of therapeutic use alone and in combination with rituximab for the treatment of DLBCL patients.
  • ||||||||||  DSP-107 / Kahr Medical
    Enrollment open:  A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies (clinicaltrials.gov) -  Feb 10, 2022   
    P1,  N=36, Recruiting, 
    DSP107 effectively (re)activated innate and adaptive anticancer immune responses and may be of therapeutic use alone and in combination with rituximab for the treatment of DLBCL patients. Not yet recruiting --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Dual signalling protein 107 triggers innate and adaptive immune response towards tumour cells () -  Aug 15, 2020 - Abstract #ITOCI2020ITOC-I_81;    
    DSP107 is a first-in-class drug candidate that can be used as a monotherapy or in combination with tumor-targeting monoclonal antibodies to trigger induction of anti-cancer immunity. DSP107 is currently tested in IND-enabling studies and clinical development is planned to commence in 2020.